Although conclusive clinical evidence for the utilization of PARP inhibitors in FA gene-mutated cancers is still lacking, a case report provided evidence that one ovarian cancer patient carrying a FANCA mutation benefitted from a PARP inhibitor (Qian et al. 2022), which suggests a potential therapeutic option for FA gene-mutated cancers. Here, FANCA is linked to cancer.